Conference Coverage

Triple threat: Novel agent shows potent T2D weight loss in phase 1


 

AT EASD 2022

Adverse effects resemble approved incretin-based agents

The study, which ran at four U.S. sites, had a primary objective of safety assessment, and Dr. Milicevic said the results showed acceptable safety and tolerability consistent with the glucagon-like peptide-1 (GLP-1) receptor agonists and tirzepatide. Like those agents, LY3437943 caused primarily mild gastrointestinal adverse effects such as nausea and diarrhea. Of the 52 patients in the study who received the triple agonist, 4 discontinued treatment because of a treatment-emergent adverse effect, including 1 patient in the subgroup who received the maximum dose.

The only concerning adverse effect noted by Dr. Haluzik was the average increase in heart rate from baseline of 10.26 beats/min in the subgroup that received the maximum dose, roughly twice the increase seen with tirzepatide and semaglutide in SURPASS-2. The average heart rate increase was about half that, 5.30 beats/min compared with baseline, in the subgroup that received a maximum weekly dose of 6 mg.

Overall, the results showed “no major adverse effects that might hamper use,” said Dr. Haluzik, an endocrinologist and professor at Charles University in Prague.

Two phase 2 studies of LY3437943 are underway and are scheduled to finish before the end of 2022. They include a study of about 300 people with type 2 diabetes that’s running at 43 U.S. sites, and a second study of about 500 people with overweight or obesity running at 28 U.S. sites.

The study was sponsored by Eli Lilly, the company developing LY3437943. Dr. Milicevic is an employee of and stockholder of Eli Lilly. Dr. Haluzik has been an adviser to, consultant to, and received honoraria and research support from Eli Lilly. He has had similar relationships with Amgen, AstraZeneca, Boehringer Ingelheim, BristolMyersSquibb, Janssen, Johnson & Johnson, Mundipharma, Novo Nordisk, and Sanofi.

Pages

Recommended Reading

SGLT2i vs DPP4i tied with reduced mortality and HF readmission risk in T2D patients with HF
Type 2 Diabetes ICYMI
Increased variability in A1c and FPG is a risk factor for severe hypoglycemia
Type 2 Diabetes ICYMI
Long-term SGLT2 inhibitor use may lower new-onset stroke risk in T2D
Type 2 Diabetes ICYMI
Mean A1c and A1c variability independently predict diabetes-related complications in T2D
Type 2 Diabetes ICYMI
Experts express caution over type 2 diabetes/tea-drinking claim
Type 2 Diabetes ICYMI
‘Game changer’ semaglutide halves diabetes risk from obesity
Type 2 Diabetes ICYMI
Waist-hip ratio beats BMI for predicting obesity’s mortality risk
Type 2 Diabetes ICYMI
Whole grains may improve survival in people with type 2 diabetes
Type 2 Diabetes ICYMI
Eat more dairy, less red meat to prevent type 2 diabetes
Type 2 Diabetes ICYMI
‘Amazing’ data for cheap beta-blocker gel for diabetic foot ulcers
Type 2 Diabetes ICYMI